WANG Ke, DONG Xian-zhe, FENG Ying-nan, WANG Zhi-zhou, ZHUANG Wei, LUAN Jia-jie, KONG Shu-jia, YUE Xiao-lin, ZHANG Lan
Objective To compare the efficacy and safety between generic in volume-based procurementand and original drug. Methods Data were collected from the hospital electronic medical record system， and the information of inpatients using azacitidine in Xuanwu Hospital of Capital Medical University，Yijishan Hospital of Wannan Medical College and Yunnan Cancer Hospital from January 1， 2019 to March 31， 2022 were collected， including basic information， disease and medication information. The patients were divided into the original drug group and the generic drug group. The basic information， treatment remission and adverse reactions of patients using azacitidine-containing chemotherapy regimen were compared. Results There were 55 patients in the generic drug （manufacturer 1） group and 53 patients in the original drug group. There were no significant differences in gender， age， height， weight， type of medical insurance， smoking， drinking， family history of cancer， treated diseases， disease classification and chronic diseases between the two groups （P>0.05）. A total of 38 patients in the generic drug （manufacturer 2） group were included， and there was no significant difference in the baseline between the two groups after propensity score matching （P>0.05）. There was no significant difference in the incidence of myelosuppression， secondary infection， gastrointestinal reaction， liver function injury， fever and fatigue between the original drug group and the generic drug group （P>0.05）. There was no significant difference in the response rate within 2 courses of treatment between the generic drug group and the original drug group （all P>0.05）. Conclusion There is no significant difference in efficacy and safety between the selected generic azacitidine and the original azacitidine.
